Praesto™ 70 CH1 Pre-Clinical Modeling: Technical Insights To Process Economic Benefits

Unlock Next-Level Bioprocessing: Discover the Power of Praesto™ 70 CH1 Resin

As biotherapeutic molecules become more complex, traditional capture and purification strategies are increasingly stretched, driving the need for more selective, high performance affinity resins. This application note presents a pre clinical modeling study of Praesto™ 70 CH1, a novel CH1 binding resin designed to address the purification challenges associated with Fab fragments and bispecific antibodies. Through head to head comparisons and process modeling, the study explores how enhanced binding capacity, extended resin lifetime, and improved pressure flow characteristics translate into meaningful process advantages.

The analysis demonstrates how Praesto 70 CH1 can deliver significant gains in productivity while reducing cost of goods, buffer consumption, facility footprint, and environmental impact. By improving impurity clearance and enabling more efficient capture, the resin offers opportunities to simplify downstream workflows and support more sustainable manufacturing strategies. The findings provide practical insight for process developers and manufacturing teams evaluating alternative capture technologies for clinical and commercial bioprocessing.